The choice Temsirolimus research buy of buffer also had some effect on the amount of specific IgG binding (see Fig. 3c, d). Table 3 Demographic, clinical and functional characteristics of the see more symptomatic patients with MDI exposure history and presumed isocyanate asthma Patient no. # Demographic data MDI exposure. (lag time) year Art of exposure

to MDI (job description) Immunological status Duration of resp. sympt (year) Lung function SPT MDI-HSA MDI-SIC MDI-HSA-specific antibodies Final clinical diagnosis Sex Age Smoking status SPT comm. allerg. Total IgE kU/L FVC  % pred FEV1  % pred NS-BHR MDI-sIgE kU/L MDI-sIgG mg/L Group A: MDI-exposed patients referred to our clinic with presumed isocyanate asthma diagnosis  1 M 29 Yes 5.5 (1) MDI-PUR glue heated; harder, binder Pos. 279 4 86 76 Pos. Pos. Pos. 13.3 <3 OAI    2 M 63 Yes 14 (0.8) MDI-PUR synthesis Pos. 1669 12 97 69 Pos. Pos. Pos. 50.4 7.3 OAI    3 M 36 Ex 3 (1) MDI-PUR manufacture; MDI-lack bystander Neg. 427 1 90 60 Pos. Pos. Pos. 4.8 9.6 OAI    4 M 34 Ex 14 (0.7) MDI-PUR glue heated, MDI cont. coatings Pos. 226 8 97 94 Pos. Pos. Pos. 3.3 <3 OAI    5 M 57 Ex 4 (0) MDI-PUR foam manufacture Pos. 61 3.4 74 78 Pos. Pos. Pos. <0.02 <3 OAI CI  6 M 54 Ex 5 (0) MDI cont. production

of elastomers Neg. 102 4 85 58 Neg. Neg. Pos. <0.02 74.0   PI  7 M 35 Ex 0.4 (0) MDI-PUR cont. check details plastic manufacture Pos. triclocarban 51 0.4 81 69 Pos. Neg. Pos.

<0.02 4.9 OAI    8 M 47 No 11.5 (0) MDI-PUR electrical potting, Neg. 15 10.5 79 68 Pos. Neg. Pos. <0.02 20.2   PI  9 M 49 Yes 11 (0) MDI-PUR manufacture of. hard plastic parts Neg. 8 2.5 85 62 Neg. Neg. Pos. <0.02 3.3 OAI    10 F 43 Yes 0.3 (0) MDI-PUR-durable elastomeric wheels,-foam Neg. 108 0.1 100 57 Pos. Neg. Pos. <0.02 14.8 A1 PI  11 M 49 Ex 13 (0.8) MDI glue, heated, plastic, wood panels Neg. 12 6 79 72 Neg. Neg. Neg. <0.02 3.6   P1  12 M 43 Ex 2 (0.2) MDI-PUR powder, acryl lack parts Neg. 2 1.5 81 73 Pos. Neg. Neg. <0.02 3.7 A1   M, Male; F, Female; comm. allerg., common allergens; MDI exp. duration of work-related exposure to MDI; lag time, lag time since last exposure; resp. sympt, duration of reported respiratory symptoms; FVC, forced vital capacity; FEV1, forced expiratory volume in 1 s; NSBHR, non-specific bronchial hyper-responsiveness; MDI-SIC, MDI-specific inhalation challenge; sIgE, MDI-specific IgE; sIgG, MDI-specific IgG. OAI, occupational MDI asthma; PI, MDI-induced hypersensitivity pneumonitis; DI, dermatitis, due to MDI; CI, conjunctivitis due to MDI; RCI, rhino-conjunctivities, due to MDI; A1, work-aggravated isocyanate asthma (aggravated by MDI exposure) at the time of blood sampling; P1, early stage of hypersensitivity pneumonitis due to MDI (isocyanate alveolitis, that is, mild clinical symptoms and non-significant changes in lung function occurred in the challenge test); n.d.